Effect of finerenone on albuminuria in patients with diabetic nephropathy a randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 314, Issue 9, 2015, Pages 884-894

  Bakris, George L ^a   Agarwal, Rajiv ^b   Chan, Juliana C ^c   Cooper, Mark E ^d   Gansevoort, Ron T ^e   Haller, Hermann ^f   Remuzzi, Giuseppe ^g,h   Rossing, Peter ^i,j,k   Schmieder, Roland E ^l   Nowack, Christina ^m   Kolkhof, Peter ^m   Joseph, Amer ⁿ   Pieper, Alexander ^o   Kimmeskamp Kirschbaum, Nina ^m   Ruilope, Luis M ^p  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^e Department of Nephrology University Medical Center Groeningen   (Netherlands)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^h Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

ⁱ STENO DIABETES CENTER   (Denmark)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

^k AARHUS UNIVERSITY   (Denmark)

^l UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^m BAYER PHARMA AG   (Germany)

ⁿ Bayer plc UK   (United Kingdom)

^o MARCO GmbH and Co KG   (Germany)

^p HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FINERENONE; LOOP DIURETIC AGENT; PLACEBO; POTASSIUM; THIAZIDE DIURETIC AGENT; CREATININE; MINERALOCORTICOID ANTAGONIST; NAPHTHYRIDINE DERIVATIVE;

ADULT; ALBUMINURIA; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCLE SPASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RENAL SYSTEM PARAMETERS; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY ALBUMIN CREATININE RATIO; AGED; ANALYSIS OF VARIANCE; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DIABETIC NEPHROPATHIES; DRUG ADMINISTRATION; DRUG EFFECTS; ETHNOLOGY; INCIDENCE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; URINE;

ADMINISTRATION, ORAL; AGED; ALBUMINURIA; ANALYSIS OF VARIANCE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERKALEMIA; INCIDENCE; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NAPHTHYRIDINES; POTASSIUM;

EID: 84940729269     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.10081     Document Type: Article

References (25)

1. Bomback AS, Kshirsagar AV, Amamoo MA, et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD.Am J Kidney Dis. 2008;51(2):199-211.
2. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001;345(12):925-926.
3. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1(5):940-951.
4. Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy. Diabetes Care. 2005;28(9):2106-2112.
5. Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;4:CD007004.
6. Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014;34(3):333-339.
7. Bärfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385-1403.
8. Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69-78.
9. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel nonsteroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur Heart J. 2013;34(31):2453-2463.
10. Ruilope LM, Agarwal R, Chan JC, et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014;40(6):572-581.
11. Kidney Disease Outcomes Quality Initiative. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5)(suppl 1):S1-S290.
12. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864-2883.
13. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.Circulation. 2004;110(8):921-927.
14. Holtkamp FA, de Zeeuw D, de Graeff PA, et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy. Eur Heart J. 2011;32(12):1493-1499.
15. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.JAm Soc Nephrol. 2009;20(8):1813-1821.
16. Schmieder RE, Schutte R, Schumacher H, et al. Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure.Diabetologia. 2014;57(10):2019-2029.
17. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011;86(5):444-456.
18. Yamout H, Lazich I, Bakris GL. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease. Adv Chronic Kidney Dis. 2014;21(3):281-286.
19. Mavrakanas TA, Gariani K, Martin PY. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy. Eur J Intern Med. 2014;25(2):173-176.
20. Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20(12):2641-2650.
21. Schmieder RE, Mann JF, Schumacher H, et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. JAm Soc Nephrol. 2011;22(7):1353-1364.
22. Lea J, Greene T, Hebert L, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease. Arch Intern Med. 2005;165(8):947-953.
23. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892-1903.
24. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204-2213.
25. Gomez-Sanchez EP, Gomez-Sanchez CE. Central regulation of blood pressure by the mineralocorticoid receptor. Mol Cell Endocrinol. 2012;350(2):289-298.